[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ball State University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":175},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,73,100,126,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100642467","postprandial-effects-of-fresh-mango-as-a-table-sugar-replacement-in-high-sugar-breakfasts-100642467",false,"NCT07650058","Postprandial Effects of Fresh Mango as a Table Sugar Replacement in High-Sugar Breakfasts.","Effects of Fresh Mango as a Table Sugar Replacement on Postprandial Intestinal Permeability and Inflammation Following a High-Sugar Breakfast.","Inclusion Criteria:\n\n* 18 - 45 years.\n* Body mass index between 18.5-35.0 kg\u002Fm2\n* Not pregnant or expecting to become pregnant (females only)\n* Not postmenopausal (females only).\n* No known chronic medical conditions (e.g., type 2 diabetes, cardiovascular disease, inflammatory diseases, etc.)\n* No history of using tobacco\u002Fillicit drugs\n* No history of using glucose-lowering medications\u002Fsupplements.\n* No history of using prescribed anti-inflammatory medications\n* Does not use over-the-counter anti-inflammatory medications ≥2x\u002Fweek\n* Does not have a pacemaker.\n* No relevant food allergies\u002Fintolerances\n* Able to lay supine for at least ten minutes.\n\nExclusion Criteria:\n\n* Not between the ages of 18-45\n* Body mass index \\\u003C 18.5 kg\u002Fm2 or \\>35.0 kg\u002Fm2\n* Pregnant (females only)\n* Postmenopausal status (females only).\n* Been diagnosed with a chronic medical conditions (e.g., type 2 diabetes, cardiovascular disease, inflammatory diseases, etc.)\n* Uses tobacco products or any illicit drugs.\n* Uses glucose-lowering drugs\u002Fsupplements.\n* Regularly takes anti-inflammatory drugs (more than 2x week).\n* Have a pacemaker.\n* Allergic to mango, wheat, gluten, and\u002For milk.\n* Unable to lay in supine position in the dark for at least ten minutes.",true,"ALL","18 Years","45 Years",{"count":21,"type":22},35,"ESTIMATED","INTERVENTIONAL",[25],"NA","Systemic inflammation and intestinal hyperpermeability (disruption of the gut barrier which allows nutrient molecules and bacteria to enter the bloodstream) are triggered by consumption of high-sugar meals and are linked to future development of cardiovascular disease (CVD). Previous research indicates that fresh mangos have properties that have positive effects on the intestinal barrier and local gut inflammation. The investigators want to understand if replacing table sugar (sucrose) with sugar from fresh mango (which also contains fiber and plant bioactives) will lead to decreased inflammatory and permeability biomarkers after eating a high-sugar breakfast. The investigators will compare the postprandial (post meal) levels of inflammatory (IL-6) and permeability (LPS, lipid binding protein (LBP), and soluble CD14) biomarkers in blood from participants who have consumed a meal sweetened with either sucrose or fresh mango.",[28],"Healthy Participants",[30,31,32],"fresh mango","inflammation","intestinal permeability","RECRUITING","2026-06-10",{"date":36,"type":37},"2026-06-16","ACTUAL",{"date":39,"type":37},"2026-02-01",{"date":41,"type":22},"2027-01",{"name":43,"class":44},"Ball State University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100635941","gut-immune-and-vascular-health-in-metabolically-healthy-obesity-100635941","NCT07559227","Gut, Immune, and Vascular Health in Metabolically Healthy Obesity","Impaired Gut-Vascular Axis as a Unique Driver of Cardiovascular Disease in Metabolically Healthy Obesity","Inclusion Criteria:\n\n* 18-55 years old.\n* BMI is 18.5-24.9 kg\u002Fm2 or \\>30kg\u002Fm2 (part 1). BMI \\> 30 kg\u002Fm2 (part 2)\n* Not pregnant or expecting to become pregnant (females only).\n* Not postmenopausal (females only).\n* Have 0-1 risk factors based on blood pressure, blood sugar, triglycerides, and HDL-cholesterol (\"good cholesterol\").\n* Have not been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).\n* Have not been diagnosed with a chronic inflammatory or gastrointestinal condition (e.g., rheumatoid arthritis, inflammatory bowel disease).\n* Do not regularly take anti-inflammatory drugs (more than 2x week) or are able to temporarily suspend use of anti-inflammatory drugs three days prior to the study visit.\n* Have not taken antibiotics or probiotics in the last month.\n* Do not use lipid-lowering drugs (e.g., statins), glucose-lowering drugs (e.g., metformin), or anti-hypertensive drugs.\n* Do not use weight-loss drugs (e.g., Ozempic, Wegovy).\n* Have not had any surgery that alters the stomach\u002Fgastrointestinal tract (e.g., gastric sleeve, gastric bypass).\n* Do not use tobacco products or any illicit drugs.\n* Do not have a pacemaker.\n* Do not have dietary restrictions prohibiting consumption of the provided meal (e.g., vegan\u002Fvegetarian diets, gluten-free diet, relevant food allergies).\n* Able to stay in the supine position in the dark for at least 10 minutes (related to vascular measurements)\n\nExclusion Criteria:\n\n* Not 18-55 years old.\n* BMI is not 18.5-24.9 kg\u002Fm2 or \\>30kg\u002Fm2 (part 1). BMI is not \\> 30 kg\u002Fm2 (part 2)\n* Pregnant or expecting to become pregnant (females only).\n* Postmenopausal (females only).\n* Do not have 0-1 risk factors based on blood pressure, blood sugar, triglycerides, and HDL-cholesterol (\"good cholesterol\").\n* Have been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).\n* Have been diagnosed with a chronic inflammatory or gastrointestinal condition (e.g., rheumatoid arthritis, inflammatory bowel disease).\n* Regularly take anti-inflammatory drugs (more than 2x week) or are unable to temporarily suspend use of anti-inflammatory drugs three days prior to the study visit.\n* Have taken antibiotics or probiotics in the last month.\n* Use lipid-lowering drugs (e.g., statins), glucose-lowering drugs (e.g., metformin), or anti-hypertensive drugs.\n* Use weight-loss drugs (e.g., Ozempic, Wegovy).\n* Have had any surgery that alters the stomach\u002Fgastrointestinal tract (e.g., gastric sleeve, gastric bypass).\n* Use tobacco products or any illicit drugs.\n* Have a pacemaker.\n* Have dietary restrictions prohibiting consumption of the provided meal (e.g., vegan\u002Fvegetarian diets, gluten-free diet, relevant food allergies).\n* Not able to stay in the supine position in the dark for at least 10 minutes (related to vascular measurements)","55 Years",{"count":55,"type":22},70,[25],"The investigators seek to better understand how a single high-fat meal impacts gut, immune, and vascular outcomes in individuals with \"metabolically healthy obesity\" (obesity and largely normal cardiometabolic profile) and \"metabolically healthy normal-weight individuals.\" Second, the investigators seek to understand how a prebiotic fiber (inulin) impacts gut, immune, and vascular outcomes in individuals with \"metabolically healthy obesity.\"",[59],"Metabolically Healthy Obesity",[61,62,63,64],"Gut-vascular axis","Intestinal permeability","vascular function","obesity","2026-04-23",{"date":67,"type":37},"2026-04-30",{"date":69,"type":37},"2026-03-01",{"date":71,"type":22},"2027-12",{"name":43,"class":44},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":16,"sex":80,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":45},"100578992","effects-of-body-composition-on-vascular-health-in-females-with-a-healthy-body-weight-100578992","NCT06818500","Effects of Body Composition on Vascular Health in Females With a Healthy Body Weight","Resting Indicators of Vascular Health and Cardiovascular Reactivity in Females With \"Normal-Weight Obesity\"","Inclusion Criteria:\n\n* You are 18-50 years old\n* Your biological sex is female\n* BMI is in \"normal\" category (18.5-24.9 kg\u002Fm2) - this BMI requirement is due to our research aims\n* You are not pregnant or expecting to become pregnant\n* You are not postmenopausal\n* You have not been diagnosed with a cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes)\n* You have not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).\n* You do not regularly take anti-inflammatory drugs (more than 2x week) or are able to temporarily suspend use of anti-inflammatory drugs.\n* You do not use lipid-lowering drugs (e.g., statins), glucose-lowering drugs (e.g., metformin) tobacco products, or any illicit drugs\n* You do not have a pacemaker.\n* You do not have dietary restrictions prohibiting you from eating the provided meal (e.g., vegan\u002Fvegetarian diets, gluten-free diet, relevant food allergies).\n* You are able to stay in the supine position in the dark for at least 10 minutes\n\nExclusion Criteria:\n\n* You are not 18-50 years old\n* Your biological sex is not female\n* Your BMI is not in the \"normal\" category (18.5-24.9 kg\u002Fm2) - this BMI requirement is due to our research aims\n* You are pregnant or expecting to become pregnant (females only)\n* You are postmenopausal\n* You have been diagnosed with a cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes)\n* You have been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).\n* You regularly take anti-inflammatory drugs (more than 2x week) or are unable to temporarily suspend use of anti-inflammatory drugs.\n* You use lipid-lowering drugs (e.g., statins), glucose-lowering drugs (e.g., metformin) tobacco products, or any illicit drugs\n* You have a pacemaker.\n* You do have dietary restrictions prohibiting you from eating the provided meal (e.g., vegan\u002Fvegetarian diets, gluten-free diet, relevant food allergies).\n* You are unable to stay in the supine position in the dark for at least 10 minutes","FEMALE","50 Years",{"count":83,"type":22},30,[25],"Most of the time, body weight is evaluated by looking at the ratio of your weight to your height. This measurement is called body mass index or BMI. However, BMI does not account for what your body is actually made up of (e.g., body fat versus muscle), which may be more important for determining cardiovascular disease risk. The investigators aim to understand vascular health in females with a \"healthy\" BMI with differing amounts of body fat and muscle mass. We will have participants come to the lab for two different study visits. At one visit, participants will eat a meal high in fat, and at the other visit, participants will undergo a stress task.",[87,88,89],"Normal-weight Obesity","BMI","Stress",[88,89,91],"Healthy BMI","2026-04-22",{"date":94,"type":37},"2026-04-24",{"date":96,"type":37},"2024-09-01",{"date":98,"type":22},"2027-05-31",{"name":43,"class":44},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":45},"100600279","impact-of-supplemental-fiber-on-gut-and-vascular-health-related-in-obesity-phenotypes-100600279","NCT07095426","Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes","Interplay Between Metabolic Risk Factors, Body Mass Index, and the Gut\u002FVascular Response to Supplemental Fiber","Inclusion Criteria:\n\n* Participants are 18-55 years old.\n* Participants BMI is ≥30 kg\u002Fm2 - this BMI requirement is due to our research aims.\n* Participants have either 0-1 or 2+ of the following risk factors outside of the normal reference ranges: blood pressure, blood sugar, triglycerides, and HDL-cholesterol.\n* Participants are not pregnant or expecting to become pregnant (females only). •Participants are not postmenopausal (females only).\n* Participants have not been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).\n* Participants have not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease, diverticulosis\u002Fdiverticulitis).\n* Participants do not regularly take anti-inflammatory drugs (more than 2x week) and are willing to suspend use of these medications for 3 days leading up to in-lab visits.\n* Participants do not take weight-loss medications (e.g., Ozempic, Wegovy).\n* Participants do not use tobacco products or any illicit drugs.\n* Participants have not used antibiotics or probiotics in the last month.\n* Participants do not have dietary restrictions prohibiting them from consuming the fiber supplement (e.g., food allergies\u002Fintolerance).\n* Participants do not have a pacemaker.\n* Participants are able to lie on their back (supine position) in the dark for at least 10 minutes (related to vascular measurements).\n\nExclusion Criteria:\n\n* Participants are not 18-55 years old.\n* Participants BMI is not ≥30 kg\u002Fm2 - this BMI requirement is due to our research aims.\n* Participants do not have either 0-1 or 2+ of the following risk factors outside of the normal reference ranges: blood pressure, blood sugar, triglycerides, and HDL-cholesterol.\n* Participants are pregnant or expecting to become pregnant (females only).\n* Participants are postmenopausal (females only).\n* Participants have been diagnosed with an advanced cardiometabolic condition (e.g., cardiovascular disease, type 2 diabetes).\n* Participants have been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease, diverticulosis\u002Fdiverticulitis). •Participants regularly take anti-inflammatory drugs (more than 2x week) and are not willing to suspend use of these medications for 3 days leading up to in-lab visits.\n* Participants take weight-loss medications (e.g., Ozempic, Wegovy).\n* Participants use tobacco products or any illicit drugs.\n* Participants have used antibiotics or probiotics in the last month.\n* Participants have dietary restrictions prohibiting them from consuming the fiber supplement (e.g., food allergies\u002Fintolerance).\n* Participants have a pacemaker.",{"count":108,"type":22},20,[25],"Based on prior research, the investigators are interested in whether an intervention targeting gut health (supplemental fiber for 9 weeks total) will improve vascular health in individuals with obesity. Additionally, the investigators are interested in if this response differs based on whether individuals with obesity have very few heart disease risk factors or several heart disease risk factors.",[112,28,59,113],"Metabolic Syndrome","Metabolically Abnormal Obesity",[115,116,117,31],"fiber","vascular health","gut health","2025-07-24",{"date":120,"type":37},"2025-07-31",{"date":122,"type":37},"2025-05-20",{"date":124,"type":22},"2027-05",{"name":43,"class":44},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":45},"100596407","glycemicinsulinemic-effects-of-fresh-mango-as-a-sugar-substitute-in-realistic-breakfasts-100596407","NCT07045051","Glycemic\u002FInsulinemic Effects of Fresh Mango as a Sugar Substitute in Realistic Breakfasts.","Effects of Fresh Mango as a Sugar Substitute Within High and Low Glycemic Breakfasts on Postprandial Glucose and Insulin","Inclusion Criteria:\n\n* 18 - 45 years.\n* Body mass index between 18.5-35.0 kg\u002Fm2\n* Not pregnant (females only)\n* Not postmenopausal (females only).\n* Not been diagnosed with cardiovascular disease.\n* Not been diagnosed with a cardiometabolic conditions (e.g., type 2 diabetes)\n* Not been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).\n* Does not regularly take anti-inflammatory drugs (more than 2x week).\n* Does not use glucose-lowering drugs (e.g., metformin)\n* Does not use lipid-lowering drugs (e.g., statins)\n* Does not use tobacco products or any illicit drugs.\n* Does not have a pacemaker.\n* Can consume mango, wheat, gluten, and milk.\n* Can stay in a supine position in the dark for at least ten minutes.\n\nExclusion Criteria:\n\n* Not between the ages of 18-45\n* Body mass index \\\u003C 18.5 kg\u002Fm2 or \\>35.0 kg\u002Fm2\n* Pregnant (females only)\n* Postmenopausal status (females only).\n* Been diagnosed with cardiovascular disease.\n* Been diagnosed with a cardiometabolic conditions (e.g., type 2 diabetes)\n* Been diagnosed with a chronic inflammatory condition (e.g., rheumatoid arthritis, inflammatory bowel disease).\n* Regularly take anti-inflammatory drugs (more than 2x week).\n* Uses glucose-lowering drugs (e.g., metformin)\n* Uses lipid-lowering drugs (e.g., statins)\n* Uses tobacco products or any illicit drugs.\n* Have a pacemaker.\n* Allergic to mango, wheat, gluten, and\u002For milk.\n* Unable to lay in supine position in the dark for at least ten minutes.",{"count":134,"type":22},24,[25],"Large blood sugar and insulin increases after meals high in table sugar are related to risk for diabetes and heart disease. Additionally, large increases in blood sugar may also negatively impact vascular health. Previous research suggests that mango consumed in small quantities has blood sugar-lowering properties, but the evidence of this within larger, more realistic meals is limited. The investigators want to understand if replacing table sugar (sucrose) with sugar from fresh mango (which also contains fiber and plant bioactives) will lead to more favorable blood sugar, insulin, and vascular responses after eating breakfast meals. The investigators will compare the postprandial glycemic, insulinemic, and vascular response to low and high glycemic meals sweetened with either fresh mango or sucrose.",[28],[139,140,30,116],"glycemia","insulinemia","2025-06-24",{"date":143,"type":37},"2025-07-01",{"date":145,"type":37},"2025-03-26",{"date":147,"type":22},"2026-12-01",{"name":43,"class":44},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":16,"sex":17,"minAge":157,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":45},"100539847","compass-across-settings-cast-for-improving-transition-outcomes-for-students-with-asd-100539847","NCT06309160","COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD","COMPASS Across Settings (CAST) for Integrating School, Home, and Community Services and Improving Transition Outcomes for Students With ASD","CAST","Inclusion Criteria:\n\n* Students with verified autism and IEPs that designate services for autism\n* Caregivers of students with autism\n* Special education teachers of students with autism\n* Pre-employment specialists of students with autism\n\nExclusion Criteria:\n\n* Not planning to move or leave their job over the school year","16 Years","99 Years",{"count":160,"type":22},297,[25],"Purpose: The purpose of this project is to develop and test the COMPASS \\[Collaborative Model for Competence and Success\\] Across Settings (CAST) intervention to enhance the goal setting and attainment skills of autistic youth. Despite federal education law mandating transition services as part of the Individualized Education Program (IEP) for ensuring good outcomes for students with disabilities, current educational practices have been unable to demonstrate that autistic students experience positive postsecondary outcomes. There are existing, evidence-based interventions aimed at supporting positive outcomes for these students. However, these interventions have not systematically provided coaching support to the caregivers, students, and employment specialists. To address these issues, CAST will integrate three evidence-based interventions for supporting student transitions while providing this critical coaching support. By doing so, CAST aims to align the priorities and goals of interventions across home, school, and community settings to better support positive postsecondary outcomes for autistic students.",[164,165,166],"Autism","Autism Spectrum Disorder","Autistic Disorder","2024-03-06",{"date":169,"type":37},"2024-03-13",{"date":171,"type":37},"2023-12-01",{"date":173,"type":22},"2027-07",{"name":43,"class":44},""]